UNIVERSITY OF CALIFORNIA, SAN FRANCISCO AUDIT & ADVISORY SERVICES

Revenue Cycle – Off-license Location Review Project #21-056

July 2021



Audit & Advisory Services

UCSF Box 0818 1855 Folsom Street San Francisco, CA 94143

tel: 415.476.3851 fax: 415.476.3326

www.ucsf.edu

July 30, 2021

Laurel Bray-Hanin

Vice President and Chief Operating Officer of Cancer Services UCSF Health

SUBJECT: Revenue Cycle-Off-License Location San Mateo Cancer Center

As a planned internal audit for Fiscal Year 2021, Audit and Advisory Services ("A&AS") conducted a review of Revenue Cycle-Off-License Location San Mateo Cancer Center. The purpose of this review was to evaluate processes for revenue cycle activities at an off-license location for governance, monitoring, and controls in place.

Our services were performed in accordance with the applicable International Standards for the Professional Practice of Internal Auditing as prescribed by the Institute of Internal Auditors (the "IIA Standards").

Our review was completed and the preliminary draft report was provided to department management in June 2021. Management provided their final comments and responses to our observations in July 2021. The observations and corrective actions have been discussed and agreed upon with department management and it is management's responsibility to implement the corrective actions stated in the report. A&AS will periodically follow up to confirm that the agreed upon management corrective actions are completed within the dates specified in the final report.

This report is intended solely for the information and internal use of UCSF management and the Ethics, Compliance and Audit Board, and is not intended to be and should not be used by any other person or entity.

Sincerely,

Irene McGlynn Chief Audit Officer

UCSF Audit and Advisory Services




EXECUTIVE SUMMARY

I. BACKGROUND

As a planned audit for Fiscal Year 2021, Audit & Advisory Services (A&AS) conducted a review of Revenue Cycle Off-License Location for the San Mateo Cancer Center. The San Mateo Cancer Center, herein referred to as "the clinic" opened on January 13, 2020; it provides advanced care to patients with cancer on the Peninsula and streamlines access to UCSF specialists and clinical trials as needed. The clinic is a part of the UCSF Helen Diller Family Comprehensive Cancer Center; however, it is not on the hospital license. For Fiscal Year 21, the clinic has approximately \$26.6 million in operating revenue, \$23 million in operating expenses, and a net income of \$3.6 million as of April 30th 2021.

The clinic is responsible for registering patients and obtaining authorization with the payor for drugs. Additionally, the clinic works collaboratively with the Medical Group Business Services (MGBS) to reduce billing denials, and limit account receivable write-offs. Bi-monthly, the clinic meets with MGBS to review its performance. Some of the reports that the clinic reviews are: Accounts Receivable Aging, Monthly Charge Lag Report, Entry Lag by Provider, Denials Dashboard, Division Request for Information Summary, and Insurance Adjustments and Patient Bad Debt. These reports help the clinic monitor performance and take corrective actions when key performance indicators are trending downward. Below is a chart of the denial rate for the San Mateo Cancer Center.



II. <u>AUDIT PURPOSE AND SCOPE</u>

The purpose of this review was to evaluate processes for revenue cycle activities at an off-license location for governance, monitoring, and controls in place. Procedures performed as part of the review include: (1) interviewed key personnel to gain an understanding of the registration and authorization process; (2) examined key procedures around registration and authorization for high cost drugs; (3) performed data analytics and identified root causes for 41 denials and 30 write-offs for the period of July 2020 to February 2021; (4) reviewed variances from targets for denials and charge lags;

(5) analyzed metrics and evaluated how they are being tracked and used; and (6) analyzed revenue cycle workflow for adherence to guidelines and leading practices as well as opportunities for improvement.

Work performed was limited to the specific activities and procedures described above. As such, this report is not intended to, nor can it be relied upon to provide an assessment of compliance beyond those areas specifically reviewed. Fieldwork was completed in May 2021.

III. SUMMARY

Based on the work performed, controls and processes for the clinic appear to be adequate. The clinic monitors its performance on a monthly basis and meets with MGBS every other month to go over key performance indicators. Currently, its professional billing denial rate is at 11.6% (for comparison, at another off-license cancer center the professional billing denial rate is at 27.2%). The total write-offs as a percentage of charges in March 2021 was 0.2% or approximately \$173k.

The specific observations from this review are listed below.

- 1. Key steps in authorization have not been documented for future training purposes.
- 2. Changes in billing instructions for an Independent Practitioner Association (IPA) were not timely communicated to responsible departments and resulted in claim denials, unnecessary billing rework, and delays in billing collection.

Additionally, one opportunity for improvement was identified in the area of establishing a dollar threshold to investigate write-offs for appropriateness.

IV. OBSERVATIONS AND MANAGEMENT CORRECTIVE ACTIONS ("MCAs")

No.	<u>Observation</u>	Risk/Effect	Recommendation	<u>MCA</u>
1	 Key steps in authorization have not been documented for future training purposes. The clinic commenced service on January 13, 2020, and there was a learning curve for staff using APeX for registration and authorization. Testing of a sample of 71 transactions identified write-offs and one denial that were processed due to staff misunderstandings in the authorization process, such as: Two write-offs totaling approximately \$97k in the sample were processed due to APeX¹ system limitation and user error. APeX only allows the user to enter one authorization expiration date, so if two drugs are authorized with different authorization expiration dates, and the later expiration date is used, the other drug¹s authorization date would have expired without anyone getting the appropriate authorization; therefore, the clinic has identified that the sooner of the two drug¹s expiration date should be used. One write-off of \$7,454 was caused by the clinic not knowing they needed to get authorization because they did not have experience with working with Medicare Advantage through Health Plan of San Mateo. One denial in the amount of \$33,802 was identified as a result of requesting treatment in cycles instead of units; this has been corrected and the billing was resubmitted. These lessons have been communicated to staff, but not written down in the form of procedures for future training purposes. 	By not documenting key procedures in the revenue cycle, new staff may not be properly trained, or errors may be repeated.	The clinic should document key steps and lessons learned in the authorization process.	Action: The clinic will update their training materials to address key steps in the authorization process and capture lessons learned. Responsible Party: Administrative Director, Cancer Center San Mateo Target Date: August 31, 2021
2	Changes in billing instructions for an Independent Practitioner Association (IPA) were not timely communicated to responsible departments and resulted in claim denials, unnecessary billing rework, and delays in billing collection.	Without a clear understanding of the DOFR for the IPAs, the clinic	The clinic should work with MGBS and Health Plan Strategy & Contracting to	Action: The clinic will coordinate with MGBS and Health Plan Strategy & Contracting

¹ APeX is the electronic health record system used by UCSF.

No.	<u>Observation</u>	Risk/Effect	Recommendation	MCA
		will get	resolve the DOFR	to resolve the DOFR
	During the review, it was noted that approximately 68% of denials were due	unnecessary	issues for the IPAs.	issues for the IPAs.
	to Division Of Financial Responsibility (DOFR) issues. There are two main IPAs that UCSF has contracts with, Mills Peninsula Medical Group (MPMG)	denials, creating billing rework for		Responsible Party:
	and Hills Physician Medical Group (HPMG). Per the new instructions for	MGBS, and a		Director, Cancer
	MPMG, drugs/injectables should be billed to the health plan, and the	delay in account		Services Regional
	administrative code should be billed to the medical group. The clinic	receivable		Expansion
	received this notification in March of 2020 and did not communicate the	collection.		
	document with MGBS until March of 2021. Additionally, the Health Plan			Target Date: August
	Strategy & Contracting wasn't aware of the changes until April of 2021. As of fieldwork, MGBS and Health Plan Strategy & Contracting are working to			31, 2021
	define the DOFR for the IPAs.		MGBS should work	Action: MGBS will
			with Clinical Systems	work with Clinical
	The DOFR rules built in APeX for off-license facilities are not the same as		to create an alt-payor	Systems to create an
	for on-license facilities, which may be adding to the additional effort required to work DOFR denials.		logic for off-license	alt-payor logic for off-
	to work DOFR defilals.		according to the IPA's	license locations to bill
			directives.	according to the IPA's
				directives.
				Responsible Party:
				Director, Patient
				Financial Services &
				Medical Group
				Business Services
				Target Date: August
				31, 2021
			Health Plan Strategy	Action, Loolth Dis:
			& Contracting should	Action: Health Plan Strategy & Contracting
			develop a	will communicate to
			communication pathway to allow the	clinics via Revenue
			sharing of future	Cycle calls and

No.	<u>Observation</u>	Risk/Effect	Recommendation	<u>MCA</u>
			billing instruction	Manager Weekly
			changes.	meetings the
				importance of
				forwarding IPA
				directives to a
				designated Health Plan
				Strategy email
				address.
				Responsible Party:
				Director, UCSF
				Medical Group &
				Physician Services,
				Health Plan Strategy &
				Contracting
				Target Date: August
				31, 2021

V. <u>OPPORTUNITIES FOR IMPROVEMENTS</u>

<u>No.</u>	<u>Observation</u>	Risk/Effect	Recommendation
1	The clinic's monthly review of denials and write-offs are done at a high level for trend	By not establishing a	The clinic should
	analysis and does not capture write-off errors at a detailed level.	risk-based approach to	consider
		investigating write-offs,	establishing a
	During the review, it was noted that MGBS made two write-off errors totaling \$895. These two	the clinic will miss the	dollar threshold to
	errors have been communicated to MGBS, and the write-offs are in the process of being reversed.	opportunity to correct	investigate write-
		write-offs made in error	offs for
	The current reports being used for monitoring and the bi-monthly meetings between the clinic and	and collect additional	appropriateness.
	MGBS focus on summary level information and trends and would not identify individual write-offs	revenue.	
	for accounts that could be collectible. While it may not be practical or cost-effective to review all		
	write-offs, without a more detailed review, the clinic may not be receiving all the revenue to which		
	it is entitled for the services performed.		